Comparative Pharmacology
Head-to-head clinical analysis: AMPYRA versus FIRDAPSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPYRA versus FIRDAPSE.
AMPYRA vs FIRDAPSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dalfampridine is a potassium channel blocker that improves conduction in demyelinated axons by prolonging action potential duration and increasing neurotransmitter release at synaptic junctions.
FIRDAPSE (amifampridine) is a potassium channel blocker that increases the release of acetylcholine from nerve terminals by prolonging the depolarization phase of the action potential, thereby enhancing neuromuscular transmission.
10 mg orally twice daily (every 12 hours). Maximum 10 mg per dose.
15 mg orally twice daily, with or without food.
None Documented
None Documented
Terminal elimination half-life approximately 5-7 hours. No clinically significant accumulation with twice-daily dosing.
Terminal elimination half-life is approximately 7-8 hours in adults with normal renal function; may be prolonged in renal impairment.
Primarily renal elimination via glomerular filtration and active tubular secretion. ~90% of administered dose excreted unchanged in urine. Fecal/biliary excretion negligible (<1%).
Primarily renal excretion as unchanged drug (~96%) with minor fecal elimination (~4%).
Category C
Category C
Potassium Channel Blocker
Potassium Channel Blocker